Drug Trial Radar · NCT07751250
Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function
Last checked: Nov 19, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Aug 14, 2026
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Arcus Biosciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 84 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the single dose PK of casdatifan between participants with moderate hepatic impairment (HI) and healthy matched control participants with normal hepatic function.
Conditions
- Healthy Participants
- Hepatic Impairment
Interventions
CasdatifanDrug
Participants will receive a 100 mg single oral dose of casdatifan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration time curve, from time 0 to the last observed non-zero concentration, of casdatifan in plasma (AUC0-t)Time frame: Up to 10 days post-dose
- Area under the concentration time curve from time 0 extrapolated to infinity of casdatifan in plasma (AUC0-inf)Time frame: Up to 10 days post-dose
- Maximum observed concentration of casdatifan in plasma (Cmax)Time frame: Up to 10 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
San Antonio, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.